![Vanya Beltrami](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Vanya Beltrami
Directeur Technique/Scientifique/R&D chez Anergis SA
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Francois Spertini | M | - |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 23 ans |
Markus Hosang | M | - |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Klaus Schollmeier | M | 67 |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Zoltán Czigler | M | - |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 13 ans |
Sten Verland | M | 67 |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Vincent Charlon | M | - |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 15 ans |
Gerard Farmer | M | - |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | 13 ans |
Alexander Kettner | M | - |
Anergis SA
![]() Anergis SA Pharmaceuticals: GenericHealth Technology Anergis SA develops allergy vaccines. It is a biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications and the firm’s vaccines are based on its IP-protected Contiguous Overlapping Peptide technology.The company was founded by Francois Spertini in August 2001 and is headquartered in Epalinges, Switzerland. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Suisse | 8 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Vanya Beltrami
- Réseau Personnel